Science2 publishers2 min readPublished
Baylor's GluePlex predicted where a molecular glue grips VAV1 before the lab confirmed it
A Baylor College of Medicine team used a structure-prediction workflow called GluePlex to find where a molecular glue grips the protein VAV1 before any experiment showed it. A separate group later reached the same conclusion in the lab.
The Scientist · Science desk
What happened
- Follow-up experiments showed the compounds act through the cell's protein-recycling system and depend on cereblon, a hub of the degradation pathway.
- The GluePlex workflow modeled how VAV1, cereblon and the glue assemble into a single three-part complex.
- The model named VAV1's SH3-2 domain as essential, and lab tests narrowed the glue's grip to a small surface loop that acts as a degron.
Compiled by The ScientistSomething wrong?How this is made
Why it matters
- capability Structure prediction becomes useful at the optimization stage, before a complex is solved, so chemists can act on a binding mechanism the bench has not yet confirmed.
- precedent A cereblon glue that reads a non-G-loop degron makes more proteins plausible degradation targets than the field had assumed.
- constraint The evidence is degradation in cells and one confirmed contact point, so whether removing VAV1 is safe and effective in a body remains open.
The order of operations matters here. GluePlex, a workflow built from AI, protein-structure prediction and physics-based modeling [14], reached the glue's contact point on VAV1 without a solved structure of the assembled complex, and the lab confirmed the prediction afterward [19]. A separate group, working from experiments, has since reported the same conclusion about VAV1 [18].
The second result concerns the shape of that loop. Most cereblon-dependent glues were thought to need a structural feature called a G-loop, and VAV1's degron is a different structure [17]. The authors read that as widening the set of proteins cereblon glues might one day degrade [20].
VAV1 is worth removing because of where it sits. It is found mainly in immune cells, where it helps activate T cells, and abnormal activity feeds T-cell lymphomas and chronic inflammatory disorders [8]. Traditional drugs block one function of a protein. Degraders remove the whole protein, and the team argues that can give a more complete effect [9]. "These compounds bring a target protein to the cell's natural protein-disposal machinery, which destroys the target," said Wang, who directs Baylor's Center for NextGen Therapeutics [6][5].
The compounds came from a screen. The team used high-throughput proteomics, which reads thousands of proteins at once [11]. Lin, a postdoctoral researcher in Wang's lab, said the analysis "revealed a series of compounds, including NGT-201-12, that caused VAV1 levels to drop while affecting relatively few other proteins" [10][12]. Follow-up work tied that degradation to cereblon [13].
The study shows degradation in cells and one confirmed contact point in a model, published in Nature Communications [2][16]. It does not show that removing VAV1 treats a lymphoma or an autoimmune disorder in an animal. And it confirms one prediction on one complex, not a success rate across many targets. The paper's broader claim, that this modeling lets chemists refine compounds before experiments reveal how they act, rests for now on this one worked example [4].
What to watch
- Whether GluePlex predictions hold up when tested against many target proteins, not just VAV1, which would establish an actual hit rate.
- Animal studies testing whether degrading VAV1 changes disease in T-cell lymphoma or inflammatory models.
- How the medicinal-chemistry work on NGT-201-12 changes the compounds' potency and selectivity.